Acuta Capital Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acuta capital partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acuta Capital Partners Today - Breaking & Trending Today

Norbert W. Bischofberger Purchases 1,378,901 Shares of Kronos Bio, Inc. (NASDAQ:KRON) Stock

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) CEO Norbert W. Bischofberger acquired 1,378,901 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were acquired at an average cost of $0.88 per share, with a total value of $1,213,432.88. Following the transaction, the chief executive officer now directly […] ....

United States , Kronos Bio , Norbertw Bischofberger , Acuta Capital Partners , Marquette Asset Management , Cerity Partners , Kronos Bio Company Profile , Virtu Financial , Acadian Asset Management , Securities Exchange Commission , Kronos Bio Inc , Get Free Report , Exchange Commission , Asset Management , Capital Partners , Kronos Bio Daily ,

Avoro Capital Advisors LLC Purchases 430,555 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Avoro Capital Advisors LLC lifted its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 11.0% during the fourth quarter, Holdings Channel reports. The firm owned 4,355,555 shares of the company’s stock after acquiring an additional 430,555 shares during the period. Avoro Capital Advisors LLC’s holdings in Taysha Gene Therapies were […] ....

Piper Sandler , Canaccord Genuity Group , Taysha Gene Therapies Inc , Acuta Capital Partners , Avoro Capital Advisors , Vanguard Group Inc , Needham Company , Citigroup Inc , Jefferies Financial Group , Holdings Channel , Taysha Gene Therapies , Free Report , Capital Advisors , Capital Partners , Vanguard Group , Gene Therapies , Get Free Report , Financial Group , Visit Holdingschannel , Taysha Gene Therapies Daily ,

DLD Asset Management LP Acquires New Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

DLD Asset Management LP acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the company’s stock, valued at approximately $223,000. DLD Asset Management LP owned about […] ....

Robertw Baird , York Mellon Corp , Praxis Precision Medicines Inc , Jefferies Financial Group , Exchange Commission , Citigroup Inc , Acuta Capital Partners , Silverarc Capital Management , Praxis Precision Medicines , Free Report , Capital Partners , Capital Management , New York Mellon Corp , Precision Medicines , Get Free Report , Visit Holdingschannel , Praxis Precision Medicines Daily ,

GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update

GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) was the recipient of a large drop in short interest in May. As of May 15th, there was short interest totalling 2,340,000 shares, a drop of 61.6% from the April 30th total of 6,090,000 shares. Based on an average daily volume of 1,570,000 shares, the days-to-cover ratio is […] ....

United States , Glycomimetics Inc , Associates Inc , Glycomimetics Company Profile , Vanguard Group Inc , Acuta Capital Partners , Get Free Report , Capital Partners , Vanguard Group , Capital One Financial , Glycomimetics Daily ,

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month […] ....

Karenm Anderson , Td Asset Management Inc , Centessa Pharmaceuticals , Institutional Trading Of Centessa Pharmaceuticals , Insider Activity At Centessa Pharmaceuticals , Centessa Pharmaceuticals Stock Performance , Analyst Recommendations For Centessa Pharmaceuticals , News Ratings For Centessa Pharmaceuticals Daily , Acuta Capital Partners , Affinity Asset Advisors , Rathbones Group , Get Free Report , Marketbeat Ratings , Management Inc , Asset Advisors , Capital Partners , Get Free , Centessa Pharmaceuticals Daily ,